Search results
Novavax Unusual Options Activity For May 23 - Novavax (NASDAQ:NVAX)
Benzinga· 15 hours agoLoading... Loading... Deep-pocketed investors have adopted a bearish approach towards Novavax NVAX , and it's something market players shouldn't ignore. Our tracking of public ...
3 Things You Need to Know If You Buy Novavax Today | The Motley Fool
The Motley Fool· 2 days agoNovavax (NVAX 5.30%) stock has both soared and plummeted at times in recent years. Investors...
Why Novavax (NVAX) Stock Price Appreciated 14% on Monday
Zacks via Yahoo Finance· 3 days agoNovavax (NVAX) surges after one of its top shareholders drops a proxy campaign against the company....
Shah Capital ends campaign against Novavax board after Sanofi deal
Reuters· 4 days agoUnder a deal signed on May 10, the French drugmaker will take a 4.9% stake in Novavax for $70...
Novavax Sees Unusually Large Options Volume (NASDAQ:NVAX)
ETF DAILY NEWS· 1 day agoNovavax, Inc. (NASDAQ:NVAX – Get Free Report) was the target of some unusual options trading activity on Wednesday. Novavax has a 1 year low of $3.53 and ...
The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom
InvestorPlace· 21 hours agoNovavax (NASDAQ:NVAX) stock was among the laggards in the race for the vaccine against COVID-19....
Better Buy: Inovio Pharmaceuticals vs. Novavax
Motley Fool via Yahoo Finance· 2 days agoThe COVID-19 vaccine was worth tens of billions of dollars, but most of it went into the hands of Moderna and Pfizer. Smaller biotechs that tried to...
Could Novavax Become the Next Moderna?
The Motley Fool via AOL· 7 days agoNovavax (NASDAQ: NVAX) and Moderna (NASDAQ: MRNA) both entered the coronavirus vaccine race around the same time, in early pandemic days, and their...
Is Novavax Stock a Buy?
Motley Fool via Yahoo Finance· 6 days agoNovavax (NASDAQ: NVAX) has been a highly volatile stock in recent years, and that volatility is on full display again this month. Shares of the...
This Stock Just More Than Doubled in 1 Day: Is It a Buy?
The Motley Fool via AOL· 5 days agoVaccine maker Novavax (NASDAQ: NVAX) isn't dead in the water after all. Though the past 18 months have been tough -- and management warned investors that the business might ...